There was a time when pharmaceutical companies largely avoided obesity. The science was incomplete, regulatory pathways were unclear, clinical trial failures outnumbered successes, and reimbursement prospects were uncertain at best. Developing weight-loss drugs was widely considered a risky bet with limited upside.
That calculation has reversed entirely. Today, obesity drug...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt